| Fund Name | Location |
| Bunge | New York, United States, White Plains |
| Caitong Securities | China, Hangzhou, Zhejiang |
| Future Money | Seoul, Seoul-t'ukpyolsi, South Korea |
| Harbinger Capital Partners | New York, New York, United States |
| ION Crossover Partners | Israel, Tel Aviv, Tel Aviv District |
| Meritage Group LP | California, San Francisco, United States |
| New World Group | China, Huangpu, Shanghai |
| Nexstar Financial | Missouri, Saint Charles, United States |
| Reid Hoffman Foundation | - |
| Shanxi Heling Touzi guanli Co., Ltd. | China, Shaanxi, Xian Shi |
| SK Impact Fund | Japan, Tokyo |
| Source Interlink Companies | Bonita Springs, Florida, United States |
| Tekelec International | Morrisville, North Carolina, United States |
| The Photonics Fund | California, Redwood City, United States |
| TheNetValue | - |
| Tianda Pharmaceuticals | China, Hong Kong, Hong Kong Island |
| Verium AG | Switzerland, Zürich, Zurich |
| Wuhan Optics Valley Elite Investment Management | China, Hubei, Wuhan |
| Xinyu Tongrong Gongxing Touzi | China, Jiangxi, Xinyu |
| Zaffre Investments | Boston, Massachusetts, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Skyhawk Therapeutics | $8M | 23 Jan 2018 | Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Skyhawk Therapeutics | $8M | 23 Jan 2018 | Massachusetts, United States |
